Epigallocatechin-3-gallate ameliorates glucolipid metabolism and oxidative stress in type 2 diabetic rats

Wenru Li¹, Chaonan Zhu¹,4, Tianheng Liu¹,2,3, Weifang Zhang⁵, Xu Liu¹,2,3, Peng Li¹,2,3, Tiantian Zhu¹,2,3

Abstract

Aims: The objective of this study was to explore the effects of epigallocatechin-3-gallate (EGCG) on type 2 diabetes mellitus (T2DM).

Main methods: Male Sprague–Dawley rats were allocated into six groups. The control group received a conventional diet. The diabetic group received a high-sucrose high-fat (HSHF) diet for 4 weeks and then was fasted and injected with streptozotocin (STZ); subsequently, the rats received a HSHF diet for another 4 weeks to develop diabetes. The four treatment groups were diabetic rats that received intragastric metformin (500 mg/kg/day) or EGCG (25, 50, and 100 mg/kg/day) for 10 weeks. All groups except the control group received a HSHF diet throughout the experiment. Several biochemical parameters such as fasting blood glucose (FBG), postprandial blood glucose (PBG), liver glycogen, muscle glycogen, fasting serum insulin (FSI), homeostasis model of insulin resistance (HOMA-IR), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), free fatty acids (FFA), superoxide dismutase (SOD), and malondialdehyde (MDA) were measured to assess the effects of EGCG on glycemic control, insulin resistance, lipid profile, and oxidative stress. Furthermore, oxidative stress in pancreatic islet β cells was detected by dihydroethidium staining.

Key findings: A HSHF diet and STZ injection induced T2DM, as indicated by changed blood glucose and body weight, which was accompanied by insulin resistance, an altered lipid profile, and oxidative stress. Interestingly, EGCG treatment dose-dependently recovered these indexes.

Significance: EGCG successfully ameliorated glycemic control and insulin sensitivity while reducing the lipid profile and oxidative stress in a T2DM rat model.

Keywords
Epigallocatechin-3-gallate, type 2 diabetes mellitus, glycemic control, insulin resistance, lipid profile, oxidative stress

Key messages
Epigallocatechin-3-gallate can treat type 2 diabetes mellitus.
Introduction

According to the eighth edition of the Global Diabetes Map released by the International Diabetes Federation (IDF), there are currently 425 million people with diabetes worldwide, and it is estimated that there will be nearly 700 million people with diabetes by 2045. Among them, patients with type 2 diabetes mellitus (T2DM) account for more than 90%.

T2DM significantly increases the financial burden of the world. T2DM is mainly characterized by elevated blood sugar, which can damage insulin signaling and cause insulin resistance. Clinically, insulin injections or oral hypoglycemic drugs are typically used to control the development of T2DM, but new hypoglycemic drugs are needed.

Insulin resistance is the main pathogenesis of T2DM. Insulin resistance refers to decreasing insulin sensitivity and/or insulin secretion. Recent studies in patients with T2DM demonstrated that indices of oxidative stress were increased, the antioxidant defense system was weakened, and islet \( \beta \) cells were more vulnerable to oxidative damage and apoptosis than other cells, thus inhibiting insulin secretion and causing insulin resistance.

Oxidative stress can also affect sugar and lipid metabolism, resulting in metabolic disorders. Additionally, oxidative stress can promote the release of inflammatory factors and lead to vascular endothelial injury, resulting in atherosclerosis.

Tea originates in China and has a long history. In recent years, tea has been studied extensively, and tea polyphenols are the main active ingredients. Epigallocatechin-3-gallate (EGCG) is a catechin monomer isolated from tea and the component with most biological activity among tea polyphenols. Ueda-Wakagi, Manabu et al. Green Tea Ameliorates Hyperglycemia by Promoting the Translocation of Glucose Transporter 4 in the Skeletal Muscle of Diabetic Rodents.

Hyperglycemia by Promoting the Translocation of Glucose Transporter 4 in the Skeletal Muscle of Diabetic Rodents.

Materials and methods

Animals

Age-matched, male Sprague–Dawley rats (SCXK (豫) 2017-0001) weighing 150 to 180 g were obtained from the Laboratory Animal Center, Zhengzhou University, China. All experimental protocols were administrated in strict accordance with the Guidance of the Laboratory Animal Center of Henan Province, Xinxiang Medical University.

Rats were maintained at 25°C under a 12-h light/12-h dark cycle. After a 1-week adaptation period, animals with a body weight of 180 ± 15 g were randomized into six groups (n=6–8 per group). The animal experiments are detailed in Table 1.

Tissue harvesting

The bodyweights of all rats were measured each week during the experimental period. At the end of the 18-week study period, all animals were killed by cervical dislocation, and the liver, skeletal muscle, and pancreas were collected. Blood was collected via cardiac puncture and centrifuged at 4000 rpm for 15 min at 4°C to isolate serum. Both serum and part of the tissue samples were stored in the freezer at −80°C for biochemical analysis. The remaining part of the freshly isolated pancreas was used for dihydroethidium staining.

Metabolic parameters

Fasting blood glucose (FBG) and postprandial blood glucose (PBG) levels were measured each week during the experimental period using a blood glucometer (One Touch®UltraVue, Johnson & Johnson Medical Ltd., Shanghai). Serum glycosylated hemoglobin A1c (HbA1c) levels were estimated by the method described by Wolfram S, et al., and muscle and hepatic HbA1c levels were determined according to the method provided by Macauley et al. Fasting serum insulin (FSI) levels were evaluated using a rat insulin enzyme-linked immunosorbent assay (ELISA) kit (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer’s protocol. Homeostasis model of insulin resistance (HOMA-IR) is the gold standard for estimating insulin resistance and is derived using the following equation

\[
\text{HOMA-IR} = \frac{\text{FBG (mmol/L)} \times \text{FSI (mU/L)}}{22.5}.
\]

Lipid profiles, cardiovascular risk indices, and antiatherogenic index (AAI)

Serum levels of total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) were determined using an automated blood analyzer (Bayer Corp.)
Kansas, USA) via a colorimetric method. Commercial kits for measuring TG (sensitivity, 10 mg/dL), TC (sensitivity, 10 mg/dL), and HDL-C (sensitivity, 10 mg/dL) were purchased from Siemens (Nashik, Maharashtra, India). Serum low-density lipoprotein cholesterol (LDL-C) levels were derived from the equation12: LDL-C = TC − (TG/5) + HDL-C; serum levels of very low-density lipoprotein cholesterol (VLDL-C) were calculated using the formula13:

\[ VLDL-C = \frac{TG}{5} \]

Cardiovascular risk indices were determined using the following formulae14: cardiovascular risk index 1 = TC/HDL-C; cardiovascular risk index 2 = LDL-C/HDL-C. The AAI was calculated using the formula15:

\[ AAI = \frac{HDL-C \times 100}{TC - HDL-C} \]

Malondialdehyde and superoxide dismutase levels in pancreas homogenates

The pancreatic contents of malondialdehyde (MDA) and superoxide dismutase (SOD) were measured as follows. The pancreas was thawed, weighed, and homogenized with 0.9% saline. Then, the homogenate was centrifuged (12,000 × rpm, 15 min, 4°C) and the supernatant was used immediately for measuring MDA and SOD levels with commercial kits (Nanjing Jiancheng Biological Engineering Institute, Nanjing, China).

Dihydroethidium staining

Reactive oxygen species (ROS) levels in the pancreas were measured using dihydroethidium. After harvesting, the pancreas was immediately embedded in optimum cutting temperature compound in liquid nitrogen. Unfixed frozen samples were cut into 5-μm thick sections and placed on glass slides. Dihydroethidium (10 μM) was applied to each tissue section, and then the sections were cover slipped. The slides were incubated in a dark humidified chamber at 37°C for 30 min. Ethidium fluorescence (excitation at 490 nm, emission at 610 nm) was examined by fluorescence microscopy (Olympus IX71, Tokyo, Japan).

Table 1. Animal experimental treatments.

| Group  | Treatment                                                                 |
|--------|---------------------------------------------------------------------------|
| Control| A conventional diet was used for 18 weeks                                 |
| Model  |                                                                            |
|        | Rats were fed a HSHF diet for 4 weeks, fasted for 20 h, and then injected with 30 mg/kg streptozotocin (STZ, Sigma Chemical Company, St. Louis, Missouri) through the tail vein. STZ was dissolved in sodium citrate saline buffer (pH 4.5) and injected immediately within a few minutes to avoid degradation. After injection, the rats were fed a HSHF diet for another 4 weeks to develop diabetes. The diabetic rats continued to receive a HSHF diet for 10 weeks. + metformin Diabetic rats received intragastric administration of 500 mg/kg metformin for the last 10 weeks |
| + EGCG (L) | Diabetic rats received intragastric administration of 25 mg/kg EGCG for the last 10 weeks |
| + EGCG (M) | Diabetic rats received intragastric administration of 50 mg/kg EGCG for the last 10 weeks |
| + EGCG (H) | Diabetic rats received intragastric administration of 100 mg/kg EGCG for the last 10 weeks |

EGCG: epigallocatechin-3-gallate, HSHF: high-sucrose-high-fat.

The HSHF diet (sucrose:lard:conventional feed = 20:20:60) was given to all rats throughout the treatment period, except for the control group.

Statistical analysis

SPSS software (Version 18) was used for statistical analyses. Data are expressed as mean ± SEM. Statistical analyses were performed using unpaired Student’s t-tests for two groups or one-way ANOVA with Newman–Student–Keuls tests for multiple comparisons. Differences were considered statistically significant when \( p < 0.05 \).

Results

Effect of EGCG on blood glucose

A high-sucrose high-fat diet and STZ injection resulted in detrimental effects on rat health. Specifically, the rats developed T2DM with a significant increase in FBG and PBG concentrations in serum (Figure 1(a) and (b)), a rise in fasting serum HbA1c levels (Figure 1(c)), and a decrease in muscle and liver glycogens (Figure 1(d)). However, after 10 weeks of metformin (500 mg/kg/day) or EGCG (25, 50, and 100 mg/kg/day) treatment, FBG, PBG, HbA1c, muscle and hepatic glycogen levels were decreased significantly compared with diabetic rats. Moreover, the hypoglycemic effect of EGCG (50 and 100 mg/kg/day) produced an equivalent or stronger effect than metformin in diabetic rats.

Effect of EGCG on body weight, insulin levels, and insulin resistance

During the 10 weeks of treatment, the body weights of all experimental rats were recorded and are shown in Figure 2(a). During 10 weeks, there was a significant increase in body weight in diabetes rats. However, after treatment with metformin (500 mg/kg/day) and EGCG (25, 50, and 100 mg/kg/day) treatment, FBG, PBG, HbA1c, muscle and hepatic glycogen levels were decreased significantly compared with the diabetes group. Moreover, the hypoglycemic effect of EGCG (50 and 100 mg/kg/day) produced an equivalent or stronger effect than metformin in diabetic rats.
group. After 1 week of treatment, metformin and EGCG had no effect on FSI. However, HOMA-IR values were decreased significantly by metformin or EGCG (50 and 100 mg/kg/day) treatment. With the progression of diabetes, FSI was reduced in the diabetes group. However, metformin or EGCG (25, 50, and 100 mg/kg/day) increased FSI levels compared with the diabetes group. In brief, FSI levels were decreased but HOMA-IR values remained high in the diabetes group; metformin (500 mg/kg/day) or EGCG (25, 50, and 100 mg/kg/day) elicited a significant increase in FSI and decline in HOMA-IR values.

**Effect of EGCG on the lipid profile of experimental rats**

Fasting TC, TG, HDL-C, LDL-C, VLDL-C, and free fatty acids (FFA) levels can also be used as indicators of diabetes. Figure 3 shows the blood lipid index data for all experimental rats in the first week and tenth week of treatment. TC, LDL-C, and FFA levels were decreased significantly by metformin or EGCG (50 and 100 mg/kg/day) treatment. With the progression of diabetes, FSI was reduced in the diabetes group. However, metformin or EGCG (25, 50, and 100 mg/kg/day) increased FSI levels compared with the diabetes group. In brief, FSI levels were decreased but HOMA-IR values remained high in the diabetes group; metformin (500 mg/kg/day) or EGCG (25, 50, and 100 mg/kg/day) elicited a significant increase in FSI and decline in HOMA-IR values.

**Effect of EGCG on cardiovascular risk indices and AAI**

Cardiovascular risk indices and AAI of all experimental groups are shown in Figure 4. After 10 weeks of high-sucrose high-fat feeding, cardiovascular risk indices (Figure 4(a) and (b)) and AAI were increased in diabetic versus control rats. However, oral administration of EGCG (100 mg/kg/day) and metformin (500 mg/kg/day) to diabetic rats markedly alleviated the altered cardiovascular risk indices and AAI. Moreover, EGCG (100 mg/kg/day) was closer to the normal group than metformin, which indicated that EGCG has an application prospect.

**Effect of EGCG on antioxidants**

Figure 5 illustrates serum SOD and MDA levels after 10 weeks of high-sucrose high-fat feeding in all experimental groups. SOD (Figure 5(a)) levels were increased, whereas MDA (Figure 5(b)) levels were decreased in diabetic versus control rats. Oral administration of EGCG (100 mg/kg/day) and metformin (500 mg/kg/day) for 5 weeks significantly alleviated the changes in serum SOD and MDA levels in diabetic rats. Figure 6 demonstrates that ROS levels were increased significantly in diabetic rats compared with control rats. Ten weeks of metformin (500 mg/kg/day) or EGCG treatment decreased ROS levels, indicating that EGCG and metformin exhibited antioxidant activity.
Discussion

In this study, we first investigated the effect of EGCG on blood glucose regulation in type 2 diabetic rats. Previous studies demonstrated that the effect of EGCG on blood glucose was dose-dependent. Here, the levels of FBG, PBG, and HbA1c were decreased significantly and muscle and liver glycogen were increased in diabetic rats treated with metformin (500 mg/kg/day) or EGCG (50 and 100 mg/kg/day) compared with the model group. In addition, the effects of EGCG (50 and 100 mg/kg/day) and metformin (500 mg/kg/day) on FBG were similar. Interestingly, the effect of EGCG (50 and 100 mg/kg/day) on PBG was significantly higher than that of metformin (500 mg/kg/day), and PBG is closely related to cardiovascular disease. There is a strong association between abnormal glucose metabolism and mortality. Metformin had a stronger effect at reducing HbA1c levels than EGCG during the early stage of diabetes, whereas EGCG had a stronger effect during the later stages of diabetes. HbA1c is an important risk factor for the occurrence and development of chronic diseases. An increased risk of diabetic complications has been observed even in the normal concentrations of HbA1c. Therefore, even a reduction of HbA1c within the normal values may be useful to reduce the risk of diabetes, vascular diseases and death, which suggests that EGCG exhibits cardiovascular protective effects. Muscle liver and muscle glycogen are lower in T2DM. For the regulation of liver and muscle glycogen, although the effect of EGCG was not as powerful as metformin, it still increased the liver and muscle glycogen content compared with the model group. Diabetes is a chronic disease that requires the long-term use of hypoglycemic drugs; thus, EGCG has an advantage over metformin for long-term use. Taken together, these data suggest that EGCG has great potential for the long-term use of hypoglycemia in patients with type 2 diabetes.

The pathogenesis of T2DM is mainly insulin resistance, which is related mitochondrial damage. EGCG possesses insulin-like activity and attenuates TNF-α-triggered insulin resistance by activating the insulin/IGF-1 signaling pathway, balancing the redox state, and regulating mitochondrial function. FSI levels decreased significantly in the diabetic group as diabetes progressed. Although metformin and EGCG had no significant effects on insulin at the beginning of the experiment, both treatments increased FSI levels in the tenth week. In the last stage of the experiment, HOMA-IR decreased in diabetes rats, but it was still higher compared with the control group. However, after the treatment of metformin and EGCG (50 and 100 mg/kg/day), HOMA-IR decreased and nearly reached the normal level. This suggests that EGCG may be similar to metformin in terms of increasing insulin sensitivity.

Obesity is the most dangerous factor leading to type 2 diabetes, and metformin can control body mass. In the current study, 10 weeks of treatment with EGCG (50 and

Figure 2. Effect of EGCG on body weight, insulin levels, and insulin resistance in experimental rats. (a) Body weight. (b) Insulin levels. (c) HOMA-IR. EGCG (L): epigallocatechin-3-gallate 25 mg/kg/day; EGCG (M): epigallocatechin-3-gallate 50 mg/kg/day; EGCG (H): epigallocatechin-3-gallate 100 mg/kg; HOMA-IR: homeostasis model assessment of insulin resistance. Results are presented as means ± SEM (n = 6).
Figure 3. Effect of epigallocatechin-3-gallate (EGCG) on lipid profiles in experimental rats. (a) TC, (b) TG, (c) HDL-C, (d) LDL-C, (e) VLDL, (f) FFA levels of experimental rats. EGCG (L): epigallocatechin-3-gallate 25 mg/kg/day; EGCG (M): epigallocatechin-3-gallate 50 mg/kg/day; EGCG (H): epigallocatechin-3-gallate 100 mg/kg; FFA: free fatty acids; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TC: total cholesterol; TG: triglycerides; VLDL-C: very low density lipoprotein-cholesterol. **p \(\leq 0.01\) versus control; ##p \(\leq 0.01\) versus model. Results are presented as mean ± SEM (n=6).

Figure 4. Effect of EGCG on cardiovascular risk indices and antiatherogenic index (AAI) in experimental rats. (a) LDL-C/HDL-C ratio, (b) TC/HDL-C ratio, (c) AAI of experimental rats. EGCG (L): epigallocatechin-3-gallate 25 mg/kg/day; EGCG (M): epigallocatechin-3-gallate 50 mg/kg/day; EGCG (H): epigallocatechin-3-gallate 100 mg/kg; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TC: total cholesterol. **p \(\leq 0.01\) versus control; ##p \(\leq 0.01\) versus model. Results are presented as mean ± SEM (n=6).
Li et al.

100 mg/kg/day) and metformin had the same inhibitory effect on body weight compared with the model group. The follow evidences may illuminate the mechanism. The non-covalent bond between EGCG and lipase changes the molecular conformation of lipase, thus reducing the catalytic activity of lipase. EGCG can regulate host TGR-5 and FXR signaling, leading to reduced fatty acid uptake and adipogenesis and increased fatty acid metabolism. In addition, many studies have shown that EGCG can increase energy consumption and fat utilization, thereby reducing body weight, fat mass, and triglycerides.

Cardiovascular disease is a common cause of disability and death in diabetes. More than 50% of newly diagnosed diabetic patients had signs of cardiovascular disease, and atherosclerosis was the leading cause of diabetes-related deaths. T2DM can cause metabolic disorders that result in an imbalance in the regulation of lipoproteins and specifically an increase in LDL and VLDL levels. Increased LDL levels are the main cause of atherosclerosis. HDL alleviates atherosclerosis by inhibiting the cellular uptake of LDL-C, thereby reducing cholesterol deposition in the arterial wall. Compared with the model group, treatment with metformin and EGCG (50 and 100 mg/kg/day) significantly decreased TC, LDL-C, and FFA levels and significantly increased HDL-C; however, neither treatment affected TG and VLDL. Oral administration of EGCG (25, 50, 100 mg/kg/day) or metformin significantly alleviated the diabetes-induced changes in cardiovascular risk indices and AAI.

Oxidative stress is an important factor in the occurrence and development of T2DM. EGCG attenuates oxidative stress and apoptosis in the bladder and also diminishes mitochondrial and endoplasmic reticulum (ER) apoptotic signaling. Furthermore, EGCG regulates mitochondria-involved autophagy, thus improving insulin resistance and glucose homeostasis in Goto–Kakizaki (GK) diabetic rats. The peroxide ions produced by oxidative stress attack the mitochondria, interfere with insulin action and secretion, and cause insulin resistance. EGCG exerts antioxidant effects by scavenging various free radicals, inhibiting the formation of ROS, nitric oxide (NO) synthesis, and enhancing the activity of antioxidant enzymes. Compared with the control group, SOD levels are increased significantly in diabetic rats. The effects of EGCG on the formation of ROS are bidirectional. Although low concentrations of EGCG can reduce the production of ROS, higher concentrations can significantly increase ROS formation; thus, we should select the appropriate dosage of EGCG that is effective but has no side effects. After 10 weeks of metformin or EGCG (25, 50, 100 mg/kg/day) treatment, SOD levels increased significantly when compared with the model group, indicating that EGCG and metformin had antioxidant capacity. In addition, EGCG (100 mg/kg/day) significantly reduced the level of MDA, which destroyed cell membranes and led to hepatocyte swelling and necrosis. This suggests that EGCG might have a better clinical application in the fight against oxidative stress.

The results of this study indicate that EGCG has great potential as an alternative or adjuvant therapy for T2DM in the future. However, the mechanism is unclear. Sundaram et al. found that green tea extract has modulatory effects on hepatic key enzymes of glucose metabolism in STZ and high fat diet induced diabetic rats. Ren et al. demonstrated that CD36 is a treatment target of EGCG in T2DM mice. EGCG down-regulated glucose levels and up-regulated C-peptide levels in T2DM mice. In summary, the current study demonstrated that EGCG modulates blood glucose in T2DM rats. EGCG down-regulated glucose levels and up-regulated C-peptide levels in T2DM mice. In summary, the current study demonstrated that EGCG modulates blood glucose in T2DM rats. Lowering blood sugar, helping maintain body mass, and reducing oxidative stress is of great significance for lipid regulation, insulin resistance, and cardiovascular protection. Therefore, EGCG may be a new type of insulin sensitizer, providing a foundation for further studies into the mechanism of action of EGCG and the molecular targets of therapeutic drugs for insulin resistance-related diseases.
Conclusion

This study demonstrated that EGCG can ameliorate glycemic control, insulin resistance, lipid profile, and oxidative stress in diabetic rats. Our results provide evidence for the clinical use of EGCG to treat T2DM. The mechanisms underlying the hypoglycemic effects of EGCG need further elucidation.

Figure 6. Effect of EGCG on pancreatic ROS levels, which were determined by dihydroethidium staining (200×). EGCG (L): epigallocatechin-3-gallate 25 mg/kg/day; EGCG (M): epigallocatechin-3-gallate 50 mg/kg/day; EGCG (H): epigallocatechin-3-gallate 100 mg/kg; ROS: reactive oxygen species.
Acknowledgements
We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation. Jian Xu, Ping Song and Guangrui Wan contributed to the paper by providing a part of regular reagents and suggestions on the revised paper.

Authorship
All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the National Natural Science Foundation of China (81800051, 81874312, 81960015, U1804197, 81673423, 1704168, 81571696, U1704175, 182300410332), Research Foundation of Henan Province (19420051005, 18HASTIT047, 2017GGJS108) and Research Foundation of Xinxiang Medical University (XYBSKYZZ201812, XYBSKYZZS05319, XYBSKYZZ201626).

ORCID iD
Tiantian Zhu https://orcid.org/0000-0001-9017-6680

References
1. Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care 2018; 41: 963–970.
2. Avogaro A. Keeping the right track in the treatment of patients with type 2 diabetes. Eur J Heart Fail 2018; 20: 52–54.
3. Kokić S, Radman M, Čapkun V, et al. Comparative assessment of the treatment of type 2 diabetes mellitus. Ann Saudi Med 2002; 22: 163–166.
4. Das P, Biswas S, Mukherjee S, et al. Association of oxidative stress and obesity with insulin resistance in type 2 diabetes mellitus. Mymensingh Med J 2016; 25: 148–152.
5. Yang H, Shi MJ, Richardson A, et al. Attenuation of leukocyte-endothelium interaction by antioxidant enzymes. Free Rad Biol Med 2003; 35: 266–276.
6. Ueda-Wakagi M, Nagayasu H, Yamashita Y, et al. Green tea ameliorates hyperglycemia by promoting the translocation of glucose transporter 4 in the skeletal muscle of diabetic rodents. Int J Mol Sci 2019; 20(10): 2436.
7. Short KR, Nair KS and Stump CS. Impaired mitochondrial activity and insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 2419–2421.
8. Raederstorff DG, Schlachter MF, Elste V, et al. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem 2003; 14: 326–332.
9. Meigs J. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol 2003; 40: S358–S361.
10. Wolfram S, Raederstorff D, Preller M, et al. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr 2006; 136: 2512–2518.
11. Macauley M, Smith FE, Thelwall PE, et al. Diurnal variation in skeletal muscle and liver glycogen in humans with normal health and Type 2 diabetes. Clin Sci 2015; 128: 707–713.
12. Venables MC, Hulston CJ, Cox HR, et al. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J Clin Nutr 2008; 87: 778–784.
13. Keske MA, Ng HL, Premilovac D, et al. Vascular and metabolic actions of the green tea polyphenol epigallocatechin gallate. Curr Med Chem 2015; 22: 59–69.
14. Nakagawa K, Okuda S and Miyazawa T. Dose-dependent incorporation of tea catechins, (−)-epigallocatechin-3-gallate and (−)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem 1997; 61: 1981–1985.
15. O’Keefe JH and Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899–904.
16. Barr E, Zimmer PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 2007; 116: 151–157.
17. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–431.
18. Jakus V and Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Rev 2004; 53(2): 131–142.
19. Palma-Duran Susana A, Vlassopoulos A, Lean M, et al. Nutritional intervention and impact of polyphenol on glycohemoglobin (HbA1c) in non-diabetic and type 2 diabetic subjects: systematic review and meta-analysis. Crit Rev Food Sci Nutr 2017; 57(5): 975–986.
20. Mi Y, Liu X, Tian H, et al. EGCG stimulates the recruitment of brite adipocytes, prevents weight gain by reducing dietary intake during insulin resistance and suppresses adipogenesis and counteracts TNF-α-triggered insulin resistance in adipocytes. Food Funct 2018; 9: 3374–3386.
21. McIntyre H, Paterson C, Ma A, et al. Metformin improves insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust NZ J Med 1991; 21: 714–719.
22. Cho M, Park JS, Nam J, et al. Association of abdominal obesity with atherosclerosis in type 2 diabetes mellitus (T2DM) in Korea. J Korean Med Sci 2008; 23: 781–788.
23. Wu X, He W, Yao L, et al. Characterization of binding interactions of (−)-epigallocatechin-3-gallate from green tea and lipase. J Agr Food Chem 2013; 61: 8829–8835.
24. Yki-Järvinen H, Nikkilä K and Mäkimattila S. Metformin therapy in patients with type 2 diabetes mellitus. Drugs Aging 1999; 58: 53–54.
25. Wang S, Moustaid-Moussa N, Chen L, et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem 2014; 25: 1–18.
26. van Greevenbroek MM, Zhang J, van der Kallen CJ, et al. Effects of interacting networks of cardiovascular risk genes...
on the risk of type 2 diabetes mellitus (the CODAM study). *BMC Med Genet* 2008; 9: 36.
27. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. *Atherosclerosis* 1996; 124: S11–S20.
28. Ohara M, Fukui T, Ouchi M, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. *Diabetes Res Clin Pract* 2016; 122: 62–70.
29. Juan YS, Chuang SM, Lee YL, et al. Green tea catechins decrease oxidative stress in surgical menopause-induced overactive bladder in a rat model. *BJU Int* 2012; 110: E236–E244.
30. Liu J, Tang Y, Feng Z, et al. (–)-Epigallocatechin-3-gallate attenuated myocardial mitochondrial dysfunction and autophagy in diabetic Goto–Kakizaki rats. *Free Radic Res* 2014; 48: 898–906.
31. Mi Y, Qi G, Gao Y, et al. (–)-Epigallocatechin-3-gallate ameliorates insulin resistance and mitochondrial dysfunction in HepG2 cells: involvement of bmal1. *Mol Nutr Food Res* 2017; 61: 1700440.
32. Nie G, Cao Y and Zhao B. Protective effects of green tea polyphenols and their major component, (–)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells. *Redox Rep* 2002; 7: 171–177.
33. Kucera O, Mezera V, Moravcova A, et al. *In vitro* toxicity of epigallocatechin gallate in rat liver mitochondria and hepatocytes. *Aging Cell* 2015; 2015: 476180.
34. Sundaram R, Naresh R, Shanthi P, et al. Modulatory effect of green tea extract on hepatic key enzymes of glucose metabolism in streptozotocin and high fat diet induced diabetic rats. *Phytomedicine* 2013; 20(7): 577–584.
35. Ren ZK, Yang ZY, Lu Y, et al. Anti-glycolipid disorder effect of epigallocatechin-3-gallate on high-fat diet and STZ-induced T2DM in mice. *Mol Med Rep* 2020; 21(6): 2475–2483.

**Appendix**

**Notation**

| Acronym | Definition |
|---------|------------|
| AAI | antiatherogenic index |
| EGCG | epigallocatechin-3-gallate |
| ELISA | enzyme-linked immunosorbent assay |
| ER | endoplasmic reticulum |
| FBG | fasting blood glucose |
| FFA | free fatty acids |
| FSI | fasting serum insulin |
| GK | Goto–Kakizaki |
| HDL-C | high-density lipoprotein cholesterol |
| HOMA-IR | homeostasis model of insulin resistance |
| HSHF | high-sucrose high-fat |
| IDF | International Diabetes Federation |
| LDL-C | low-density lipoprotein cholesterol |
| MDA | malondialdehyde |
| NO | nitric oxide |
| PBG | postprandial blood glucose |
| ROS | reactive oxygen species |
| SOD | superoxide dismutase |
| STZ | streptozotocin |
| T2DM | type 2 diabetes mellitus |
| TC | total cholesterol |
| TG | triglycerides |
| VLDL-C | very low-density lipoprotein cholesterol |